Lumrotatug clinical trials
Also written CM313.
How each study uses lumrotatug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lumrotatug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
14 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 4
Keymed Biosciences Co.Ltd (10) · Institute of Hematology & Blood Diseases Hospital, China (2) · Sichuan Provincial People's Hospital (1) · Chao Ji (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test lumrotatug.
- Mar 2027Study of CM313 in Subject With IgA NephropathyPhase 2 · Keymed Biosciences Co.Ltd
- Oct 2027A Single-center Study of CM313 in Patients With PemphigusNot applicable · Sichuan Provincial People's Hospital
- Nov 2027Study of CM313(SC) Injection in Subjects With Platelet Transfusion RefractorinessPhase 1/2 · Keymed Biosciences Co.Ltd
Studies
Open first, then newest update. How each study uses lumrotatug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 3Keymed Biosciences Co.LtdNCT07910903Written as CM313
- Study of CM313 in Subject With IgA NephropathyNot yet recruitingPhase 2Keymed Biosciences Co.LtdNCT06830395Written as CM313
- Study of CM313(SC) Injection in Subjects With Platelet Transfusion RefractorinessRecruitingPhase 1/2Keymed Biosciences Co.LtdNCT06792019Written as CM313(SC) injection-low dose
- A Single-center Study of CM313 in Patients With PemphigusNot yet recruitingNot applicableSichuan Provincial People's HospitalNCT06904040Written as CM313 injection
- Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic AnemiaNot yet recruitingPhase 1/2Keymed Biosciences Co.LtdNCT06791824Written as CM313(SC) injection
- Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)Not yet recruitingPhase 2Keymed Biosciences Co.LtdNCT06791772Written as CM313 injection
- A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.Not yet recruitingPhase 1/2Chao JiNCT06663943Written as CM313 (SC)
- Study of CM313 in Healthy SubjectsRecruitingPhase 1Keymed Biosciences Co.LtdNCT06285227Written as CM313 injection
- A Study of CM313 in Subjects With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 1/2Keymed Biosciences Co.LtdNCT06126237Written as CM313 injection
- Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)Active, not recruitingPhase 2Keymed Biosciences Co.LtdNCT06594146Written as CM313 injection
- A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaCompletedPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05694767Written as CM313 Injection
- A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaActive, not recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06199089Written as CM313 Injection
- A Study of CM313 Injection in Subjects With Systemic Lupus ErythematosusStatus unknownPhase 1/2Keymed Biosciences Co.LtdNCT05465707Written as CM313 2 mg/kg
- Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaStatus unknownPhase 1Keymed Biosciences Co.LtdNCT04818372Written as CM313-Dose escalation
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call lumrotatug · ClinicalTrials.gg INT016702
- UNII (FDA) GT2R696LEMLUMROTATUGOne source FDA
- NCI Thesaurus C180505LumrotatugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | GT2R696LEM | LUMROTATUG | One source FDA |
| NCI Thesaurus | C180505 | Lumrotatug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.